Skip to content
etf.net

Launched · SEC filings

WisdomTree BioRevolution Fund

WDNACboeWisdomTreeC

$23.56−0.55 (−2.26%)

As of Nov 2, 2026, 3:59 PM ET

C40/ 100

Rank 11 of 17 in Biotech & Genomics

C40/100Rank 11 of 17inBiotech & Genomics
Intraday session: down, 73 prints from 24.11 to 23.56. Range 23.56 to 24.26. Use the arrow keys to read each point.23.8024.0024.2010 AM12 PM2 PM4 PM
Expense ratio
0.45%
Fund size
$5M
1Y total return
+46.6%
Yield · Last 12 months
3.21%
Holdings
89
Avg volume · 30D
2.58K sh
52W range
low $15.67high $25.03
Launched
Filings
SEC EDGAR

The ETF.net WDNA Grade

C

Score 40 out of 100

Category
Biotech & Genomics⁠
Rank
11 of 17
Six-pillar profile for WDNA. Scores out of 100: Cost 56, Risk 42, Mission 65, Tradability 3, Holdings 80, Durability 20. Strongest: Holdings (80). Weakest: Tradability (3). Leans toward Holdings.

Score 40 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

Very small fund, grade capped at C.

The cap holds the Score at 40 or below, so B and A are out of reach.

The pillars earned
49
This cap took
−9
Published Score
40 Grade C

  • Cost

    The fund’s net expense ratio, ranked against its category.
    B56 out of 100
    Rank 7 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    B65 out of 100
    Rank 7 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    C42 out of 100
    Rank 11 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F3 out of 100
    Rank 17 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A80 out of 100
    Rank 4 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    F20 out of 100
    Rank 16 of 17

Our read on WDNA

ETF.net Research

In short

CMost biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.

Stated mandate

The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.

Why people hold it

  • Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
  • The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
  • Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com

Worth knowing

  • A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
  • For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
  • The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com

WDNA Performance

Launched Jun 3, 2021

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
WDNA$14,663
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. WDNA $14,663. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for WDNA. Periods over one year show the average yearly return.
PeriodWDNA
Year to date+42.4%
1 month−0.2%
3 months+23.6%
1 year+46.6%
3 yearsper year+23.1%
5 yearsper year+0.1%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for WDNA
YearReturn barWDNA
2026 YTD+42.4%
2025+22.7%
2024−14.1%
2023−2.1%
2022−26.3%
2021−5.3%

Since listing, Jun 3, 2021

WDNA in the news

WDNA Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
3.21%Last 12 months
Payout per share
$0.77Last 12 months
Last payment
$0.77 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2021–2026

One bar per payment. 5 payments from 2021 to 2026 YTD. Dec 27, 2021 $0.02; Dec 23, 2022 $0.07; Dec 22, 2023 $0.14; Dec 26, 2024 $0.11; Dec 26, 2025 $0.77. Use the arrow keys to read each point.202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 26, 2025Dec 30, 2025$0.77
Dec 26, 2024Dec 30, 2024$0.11
Dec 22, 2023Dec 28, 2023$0.14
Dec 23, 2022Dec 29, 2022$0.07
Dec 27, 2021Dec 30, 2021$0.02

$10,000 in WDNA 5 years ago paid $424 in dividends.

WDNA Risk

Risk pillarC42 out of 100Rank 11 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
24.6%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.79
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−56.8%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.26
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

WDNA Cost

Compare WDNA and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$5,089

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • WDNA 0.45%

    $9,041

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • WDNA 0.45%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530WDNA $9,041IBBQ $3,952

Year by year

YearWDNAIBBQOverpaying
10$812$347$465
20$3,128$1,351$1,777
30$9,041$3,952$5,089

Other funds in Biotech & Genomics

See others